Literature DB >> 29948248

Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML.

Jeremias Motte1, Janina Kneiphof1, Katrin Straßburger-Krogias1, Anja Klasing1, Ortwin Adams2, Aiden Haghikia1, Ralf Gold3.   

Abstract

We report a 76-year-old MS patient, treated with DMF for 3 years. Lymphocytes never showed values below 1240/µl. CSF analysis revealed 1,988,880 copies/ml of JCV-DNA, JCV-DNA was detectable in serum and anti-JCV-antibody in CSF and serum were highly positive. Stratify®-JCV-test was positive. CD8-positive T-lymphocytes were reduced. Therapy with mefloquine, mirtazapine and cidofovir resulted in complete elimination of the virus in serum and 90% reduction of viral load in CSF. This case shows that despite careful monitoring for lymphopenia JCV spreading to the CSF may occur during treatment with DMF.

Entities:  

Keywords:  Dimethylfumarate; Multiple sclerosis; PML; Progressive multifocal leukoencephalopathy

Mesh:

Substances:

Year:  2018        PMID: 29948248     DOI: 10.1007/s00415-018-8931-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  7 in total

1.  PML in a patient with lymphocytopenia treated with dimethyl fumarate.

Authors:  Thorsten Rosenkranz; Mark Novas; Christoph Terborg
Journal:  N Engl J Med       Date:  2015-04-09       Impact factor: 91.245

2.  PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?

Authors:  Klaus Lehmann-Horn; Horst Penkert; Peter Grein; Ulrich Leppmeier; Sarah Teuber-Hanselmann; Bernhard Hemmer; Achim Berthele
Journal:  Neurology       Date:  2016-06-24       Impact factor: 9.910

Review 3.  Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies.

Authors:  Eugene O Major
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

Review 4.  Classifying PML risk with disease modifying therapies.

Authors:  Joseph R Berger
Journal:  Mult Scler Relat Disord       Date:  2017-01-06       Impact factor: 4.339

5.  Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.

Authors:  A H Cross; L Piccio; E E Longbrake; M J Ramsbottom; C Cantoni; L Ghezzi
Journal:  Mult Scler       Date:  2015-10-12       Impact factor: 6.312

6.  Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate.

Authors:  Moogeh Baharnoori; Jennifer Lyons; Akram Dastagir; Igor Koralnik; James M Stankiewicz
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-08-23

7.  A link between long-term natalizumab dosing in MS and PML: Putting the puzzle together.

Authors:  Eugene O Major; Avindra Nath
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-04-29
  7 in total
  4 in total

1.  Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence.

Authors:  Bhavya Narapureddy; Divyanshu Dubey
Journal:  Patient Prefer Adherence       Date:  2019-10-01       Impact factor: 2.711

Review 2.  The Use of Antimalarial Drugs against Viral Infection.

Authors:  Sarah D'Alessandro; Diletta Scaccabarozzi; Lucia Signorini; Federica Perego; Denise P Ilboudo; Pasquale Ferrante; Serena Delbue
Journal:  Microorganisms       Date:  2020-01-08

Review 3.  Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.

Authors:  Allison Lm Jordan; Jennifer Yang; Caitlyn J Fisher; Michael K Racke; Yang Mao-Draayer
Journal:  Mult Scler       Date:  2020-08-18       Impact factor: 6.312

4.  A retrospective analysis of changes in lymphocyte levels in patients with multiple sclerosis during and after Tecfidera® treatment.

Authors:  Maria-Elizabeth Baeva; Philip Boris Baev; Jill Nelson; Anna Kazimirchik; Galina Vorobeychik
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-07-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.